Evidence map›Paper›PMID 35836752›Full record

ArticleHIV/AIDS (Auckland, N.Z.)2022

Molecular Epidemiology of Human Herpes Virus Type 8 Among Patients with Compromised Immune System in Ouagadougou, Burkina Faso.

Nakougou Moϊ-Bohm Biatougou, Muriel S Ouedraogo, Serge Theophile Soubeiga, Theodora Mahoukede Zohoncon, Paul Ouedraogo, Dorcas Obiri-Yeboah, Aziz Sidi Aristide Tapsoba, Touwendpoulimdé Isabelle Kiendrebeogo, Tani Sagna, Pascal Niamba and 2 more

Open access · goldAbstract read
In one paragraph

Article in HIV/AIDS (Auckland, N.Z.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Nakougou Moϊ-Bohm BiatougouBiochemistry and Microbiology Department, Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.
Muriel S OuedraogoDepartment of Dermatology, Yalgado Ouedraogo Hospital University Centre, Ouagadougou, Burkina Faso.
Serge Theophile SoubeigaDepartment of Biomedical Research, Biomolecular Research Centre Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso.ORCID 0000-0002-9741-2428
Theodora Mahoukede ZohonconBiochemistry and Microbiology Department, Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.
Paul OuedraogoDepartment of Medicine, Saint Thomas d'Aquin University (USTA), Ouagadougou, Burkina Faso.
Dorcas Obiri-YeboahDepartment of Microbiology and Immunology, University of Cape Coast, Cape Coast, Ghana.ORCID 0000-0003-4562-9294
Aziz Sidi Aristide TapsobaBiochemistry and Microbiology Department, Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.
Touwendpoulimdé Isabelle KiendrebeogoBiochemistry and Microbiology Department, Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.ORCID 0000-0002-4684-4650
Tani SagnaDepartment of Biomedical and Public Health, Research Institute of Health Sciences (IRSS), Ouagadougou, Burkina Faso.ORCID 0000-0002-8775-0693
Pascal NiambaDepartment of Dermatology, Yalgado Ouedraogo Hospital University Centre, Ouagadougou, Burkina Faso.
Adama TraoreDepartment of Dermatology, Yalgado Ouedraogo Hospital University Centre, Ouagadougou, Burkina Faso.
Jacques SimporeBiochemistry and Microbiology Department, Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.ORCID 0000-0002-0415-9161
Université Joseph Ki-Zerbo · BFCentre Hospitalier Universitaire Yalgado Ouédraogo · BFInstitut de Recherche en Sciences de la Santé · BFUniversité Ouaga II · BFUniversity of Cape Coast · GH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Human herpesvirus type 8 (HHV-8) is the main etiological agent of Kaposi's sarcoma. This virus is frequently associated with immunocompromision. This study aimed to detect HHV-8 in people with compromised immune system. Patients and Methods: This is a cross-sectional study that included 180 subjects: 179 HIV-infected patients and 1 patient with bullous pemphigoid. Blood samples were taken from all subjects, and swabs of lesions were then taken from individuals with symptoms of Kaposi's sarcoma. Viral load and CD4 Results: Among HIV-infected persons, 13.41% had a viral load of more than 10,000 copies/mL, and 22.91% had a CD4 Conclusion: These results exposing low prevalence levels of HHV-8 in HIV-infected patients could be due to the beneficial effect of antiretroviral drugs.

Indexed as

Burkina FasoHHV-8HIVimmunocompromisedKaposi’s sarcoma

Identifiers

PMID35836752
PMCPMC9275423
OpenAlexW4284895096

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.